Akoya Biosciences Inc. said an in-depth comparison of immuno-oncology biomarker types determined that multiplex immunofluorescence with spatial characterization significantly outperformed other biomarker testing approaches for predicting patient response to treatments targeting PD-1/PD-L1.
A new study finds trends in colonoscopy rates did not fully align with the increase in colorectal cancer in younger adults, adding to evidence the rise in early onset CRC is not solely a result of more detection. The study is published online in the Journal of Medical Screening.
Lung cancer patients who had a hurricane disaster declared during radiotherapy had worse overall survival than those who completed treatment in normal circumstances, with longer disaster declarations associated with increasingly worse survival.
An MD Anderson Cancer Center study discovered a cellular pathway tied to cancer may be beneficial in reducing side effects and extending duration of immunotherapy in some patients with hepatocellular carcinoma.
The three-drug combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to results of the BEACON CRC phase III clinical trial led by researchers at MD Anderson Cancer Center.
Medical oncologists administer anticancer drug regorafenib to try to improve overall survival in patients with metastatic colorectal cancer who have ceased to respond to standard therapy. However, some of the adverse events related to the use of this drug often limits its use in clinical practice.
Researchers at the University of California, Irvine, have developed and tested on mice a therapeutic treatment that uses engineered stem cells to target and kill cancer bone metastases while preserving the bone.
Cancer took more than 8.7 million years of life and $94.4 billion in lost earnings among people ages 16 to 84 in the United States in 2015. The calculation comes from a new report by American Cancer Society researchers that appears early online in JAMA Oncology.
A team of researchers from UCLA and the University of Toronto have identified a new biomarker found in urine that can help detect aggressive prostate cancer, potentially saving hundreds of thousands of men each year from undergoing unnecessary surgeries and radiotherapy treatments.
Bristol-Myers Squibb Co. announced topline results from CheckMate-459, randomized phase III study evaluating Opdivo (nivolumab) vs. sorafenib as a first-line treatment in patients with unresectable hepatocellular carcinoma.